BVF PARTNERS L P/IL
SEC insider (Form 3/4/5 filer). CIK 0001055947. 10% Owner at Foghorn Therapeutics Inc. (FHTX) and 9 other issuers. 79 reported Form 4/5 transactions since Sep 2024; latest on Sep 16, 2026. Located in SAN FRANCISCO, CA.
Companies BVF PARTNERS L P/IL has filed insider reports for
- Foghorn Therapeutics Inc. (FHTX): 10% Owner
- IMMUNIC, INC. (IMUX): Director
- XOMA Royalty Corp (XOMA): 10% Owner
- Kymera Therapeutics, Inc. (KYMR): Director
- Olema Pharmaceuticals, Inc. (OLMA): Director
- MoonLake Immunotherapeutics (MLTX): Director, 10% Owner
- Repare Therapeutics Inc. (RPTX): 10% Owner
- ESSA Pharma Inc. (EPIX): 10% Owner
- GLYCOMIMETICS INC (CBIO): 10% Owner
- Allakos Inc. (ALLK): 10% Owner
BVF PARTNERS L P/IL
CIK: 0001055947
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (14)
Foghorn Therapeutics Inc.
IMMUNIC, INC.
XOMA Royalty Corp
Kymera Therapeutics, Inc.
Olema Pharmaceuticals, Inc.
MoonLake Immunotherapeutics
Repare Therapeutics Inc.
ESSA Pharma Inc.
GLYCOMIMETICS INC
Allakos Inc.
PALVELLA THERAPEUTICS, INC.
4D Molecular Therapeutics, Inc.
Third Harmonic Bio, Inc.
Eledon Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (79 total)
- Sep 16, 2026IMUX
IMMUNIC, INC.
AwardIndirectStock Option
25.4K shares- - Jul 14, 2026XOMA
XOMA Royalty Corp
Tender OfferDirect412K shares- - Jul 14, 2026XOMA
XOMA Royalty Corp
Tender OfferDirect2.8M shares- - Jul 14, 2026XOMA
XOMA Royalty Corp
Tender OfferDirect3.6M shares- - Jul 14, 2026XOMA
XOMA Royalty Corp
Tender OfferIndirect772K shares- - Jun 26, 2026KYMR
Kymera Therapeutics, Inc.
SaleIndirect51.9K shares at avg. $106.50$5.5M - Jun 26, 2026KYMR
Kymera Therapeutics, Inc.
SaleDirect627.6K shares at avg. $106.50$66.8M - Jun 26, 2026KYMR
Kymera Therapeutics, Inc.
SaleDirect113.3K shares at avg. $106.50$12.1M - Jun 26, 2026KYMR
Kymera Therapeutics, Inc.
SaleDirect837.9K shares at avg. $106.50$89.2M - Jun 24, 2026KYMR
Kymera Therapeutics, Inc.
AwardIndirectStock Option (Right to Buy)
6.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 16, 2026 | IMUX IMMUNIC, INC. | Award Stock Option | 25,370 | - | - | Indirect |
| Jul 14, 2026 | XOMA XOMA Royalty Corp | Tender Offer | 412,000 | - | $0 | Direct |
| Jul 14, 2026 | XOMA XOMA Royalty Corp | Tender Offer | 2,773,545 | - | $0 | Direct |
| Jul 14, 2026 | XOMA XOMA Royalty Corp | Tender Offer | 3,635,758 | - | $0 | Direct |
| Jul 14, 2026 | XOMA XOMA Royalty Corp | Tender Offer | 772,000 | - | $0 | Indirect |
| Jun 26, 2026 | KYMR Kymera Therapeutics, Inc. | Sale | 51,858 | $106.50 | $5,522,877 | Indirect |
| Jun 26, 2026 | KYMR Kymera Therapeutics, Inc. | Sale | 627,597 | $106.50 | $66,839,081 | Direct |
| Jun 26, 2026 | KYMR Kymera Therapeutics, Inc. | Sale | 113,289 | $106.50 | $12,065,279 | Direct |
| Jun 26, 2026 | KYMR Kymera Therapeutics, Inc. | Sale | 837,914 | $106.50 | $89,237,841 | Direct |
| Jun 24, 2026 | KYMR Kymera Therapeutics, Inc. | Award Stock Option (Right to Buy) | 6,068 | - | - | Indirect |
1-10 of 79 transactions